D1692

GW4869

≥90% (NMR), powder, N-SMase inhibitor

• Sinónimos: N,N′-Bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-3,3′-p-phenylene-bis-acrylamide dihydrochloride
• Fórmula empírica (notación de Hill): C₃₀H₂₈N₆O₂ · 2HCl
• Número CAS: 6823-69-4
• Peso molecular: 577.50
• UNSPSC Code: 41121800
• PubChem Substance ID: 24724460
• NACRES: NA.77
• Assay: ≥90% (NMR)
• Form: powder
• Storage condition: desiccated, protect from light

Propiedades

• Nombre del producto: GW4869, ≥90% (NMR)
• Quality Segment: 100
• assay: ≥90% (NMR)
• form: powder
• storage condition: desiccated, protect from light
• color: light yellow to yellow
• mp: >300 °C
• solubility: DMSO: 0.2 mg/mL
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: Cl.Cl.O=C(Nc1ccc(cc1)C2=NCCN2)\C=C/c3ccc(\C=C/C(=O)Nc4ccc(cc4)C5=NCCN5)cc3
• InChI: 1S/C30H28N6O2.2ClH/c37-27(35-25-11-7-23(8-12-25)29-31-17-18-32-29)15-5-21-1-2-22(4-3-21)6-16-28(38)36-26-13-9-24(10-14-26)30-33-19-20-34-30;;/h1-16H,17-20H2,(H,31,32)(H,33,34)(H,35,37)(H,36,38);2*1H/b15-5-,16-6-;;
• InChI key: NSFKAZDTKIKLKT-LOLTXFFGSA-N

Descripción

General description

GW4869 is a commonly used pharmacological agent, which inhibits exosome generation. It blocks ceramide-mediated inward budding of multivesicular bodies (MVBs) and the release of mature exosomes from MVBs. GW4869 exhibits cytotoxicity to phosphatidylserine-expressing myeloma cells. It inhibits the secretion of IFN (interferon)-α by plasmacytoid dendritic cells (pDCs).

Application

GW4869 has been used:

• as an inhibitor of neutral sphingomyelinase and exosome biogenesis
• to analyse the effects of arsenic trioxide (ATO) treatment for hepatoma carcinoma HCCLM3 cells on ceramide production
• to determine the contributions of p75 neurotrophin receptor (p75^NTR) and tropomyosin receptor kinase A (TrkA)- coupled pathways to nerve growth factor (NGF)-induced thermal hypersensitivity in rats

Biochem/physiol Actions

A cell-permeable, potent, specific, non-competitive inhibitor of N-SMase (neutral sphingomyelinase)

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)